Last reviewed · How we verify
metoprolol plus morphine
Metoprolol reduces heart rate and blood pressure via beta-1 adrenergic blockade, while morphine provides analgesia and reduces anxiety through opioid receptor agonism and sympathetic nervous system depression.
Metoprolol reduces heart rate and blood pressure via beta-1 adrenergic blockade, while morphine provides analgesia and reduces anxiety through opioid receptor agonism and sympathetic nervous system depression. Used for Acute coronary syndrome with pain and hemodynamic management, Acute decompensated heart failure with pain, Myocardial infarction with anxiety and pain control.
At a glance
| Generic name | metoprolol plus morphine |
|---|---|
| Sponsor | Sahlgrenska University Hospital |
| Drug class | Beta-blocker plus opioid analgesic combination |
| Target | Beta-1 adrenergic receptor; mu-opioid receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular; Pain management |
| Phase | FDA-approved |
Mechanism of action
Metoprolol is a selective beta-1 blocker that decreases cardiac contractility and heart rate, reducing myocardial oxygen demand and lowering blood pressure. Morphine acts as a mu-opioid receptor agonist to provide pain relief and anxiolysis, and also causes peripheral vasodilation and reduced sympathetic tone. Together, this combination reduces cardiac workload and provides analgesia, commonly used in acute coronary syndromes and acute heart failure.
Approved indications
- Acute coronary syndrome with pain and hemodynamic management
- Acute decompensated heart failure with pain
- Myocardial infarction with anxiety and pain control
Common side effects
- Bradycardia
- Hypotension
- Respiratory depression
- Nausea
- Dizziness
- Fatigue
Key clinical trials
- Repeated Dose Study for the Investigation of Heritability of and Genetic Influences on Drug Pharmacokinetics (PHASE1)
- Pain Relief of Metoprolol Versus Metoprolol Plus Morphine in Acute Chest Pain (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- metoprolol plus morphine CI brief — competitive landscape report
- metoprolol plus morphine updates RSS · CI watch RSS
- Sahlgrenska University Hospital portfolio CI